GRAIL, Inc. (NasdaqGS: GRAL)
Health Care · Biotechnology · US
$81.62
-1.11% today · +150.7% 1Y
GRAIL, Inc. (NasdaqGS: GRAL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.69B and employs 910 people.
Over the last twelve months the share price has gained 150.7%, trading between 30.82 and 118.84.
Tweenvest scores GRAIL, Inc. across four factors: quality 34/100, value 58/100. Its strongest factor is value.
GRAL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.69B
- Revenue (TTM)
- $165.26M
- P/E
- —
- EPS
- -9.75
- Dividend yield
- —
- Beta (5Y)
- 3.25
- 52-week high
- $118.84
- 52-week low
- $30.82
- Avg volume (3M)
- —
- Shares outstanding
- 44.67M
- Employees
- 910
- Next earnings
- —
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
- ISIN
- US3847471014
- Founded
- 2015
- Listed since
- Jun 12, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.99 | +0.62% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.84 | -2.51% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.